K., Balasubramanian, A., Tatem, A
MECHANISMS OF ACTION OF GLP-1 RAs AND MULTI-AGONIST THERAPIES Incretin-based therapies leverage the physiological roles of gut-derived peptide hormones, principally glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptor (GCG) to address the multifaceted pathophysiology of MASLD
After three years, participants taking GLP-1 drugs experienced a 30% reduction in emergency department visits, a 25% reduction in hospitalizations, a 40% reduction in overdoses, and a 50% reduction in drug-related deaths
Phn t GSH c bao bc bn trong cc ti phospholipid kp (liposome) c cu trc tng t mng t bo
GLP-1 originates from the cleavage of preproglucagon, a 160-amino acid precursor whose expression, driven by the GCG gene, occurs in pancreatic -cells and intestinal cells